Cytisine liquid pharmaceutical composition patent

ChangeBridge: EPO Bulletin - Therapeutics (A61P)

Published March 25th, 2026

Detected April 2nd, 2026

Summary

The European Patent Office published EP4072517A1 on March 25, 2026, a patent application by Adamed Pharma S.A. covering a liquid pharmaceutical composition comprising cytisine. The inventors are Kubiak, Rzasa, Zarzycka, and Garbera. The patent is designated across 38 European states.

View original document View source feed page

What changed

EPO published the first publication (A1) of patent application EP4072517A1 for a liquid pharmaceutical composition containing cytisine, filed by Adamed Pharma S.A. The application covers formulations with IPC classifications including A61K 9/00, A61K 31/439, and therapeutic indications A61P 25/34 and A61P 25/00.

No compliance action is required. This is a patent publication rather than regulatory guidance. Entities in the pharmaceutical sector should note this publication for freedom-to-operate and competitive intelligence purposes if developing similar cytisine-based compositions.

Source document (simplified)

← EPO Patent Bulletin

LIQUID PHARMACEUTICAL COMPOSITION COMPRISING CYTISINE

Publication EP4072517A1 Kind: A1 Mar 25, 2026

Applicants

Adamed Pharma S.A.

Inventors

KUBIAK, Bartlomiej, RZASA, Joanna, ZARZYCKA, Mariola, GARBERA, Kamil

IPC Classifications

A61K 9/00 20060101AFI20251120BHEP A61K 47/02 20060101ALI20251120BHEP A61K 47/10 20170101ALI20251120BHEP A61K 47/18 20170101ALI20251120BHEP A61K 47/26 20060101ALI20251120BHEP A61K 47/36 20060101ALI20251120BHEP A61K 47/38 20060101ALI20251120BHEP A61K 31/439 20060101ALI20251120BHEP A24B 15/167 20200101ALI20251120BHEP A61P 25/34 20060101ALI20251120BHEP A61P 25/00 20060101ALI20251120BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →